ClinicalTrials.Veeva

Menu

Pharmacological and Non-pharmacological Treatment Effects on Children With Different Predicted Myopia Progression Rate

T

The Hong Kong Polytechnic University

Status

Enrolling

Conditions

Myopia

Treatments

Drug: Atropine 0.05%
Device: DIMS lens

Study type

Interventional

Funder types

Other

Identifiers

NCT06282848
HongKongPU_Optometry4

Details and patient eligibility

About

The goal of this clinical trial is to compare pharmacological and non-pharmacological treatment effects on the children with different predicted myopia progression rate measured by modified multifocal electroretinogram. The main questions it aims to answer are:

  • the effectiveness of using 0.05% atropine and prescribing DIMS lens for myopia control in children with different myopia progression rates
  • the contribution of L/M cones in juvenile myopia progression and changes of retinal activities under atropine and DIMS treatment.

Participants will have baseline and follow-up eye examinations and given either pharmacological treatment with 0.05% atropine or non-pharmacological treatment with DIMS lens for myopia control.

Researchers will compare the changes of refractive errors and axial length after different types of interventions and investigate the relations between the parameters of mfERG responses and the thicknesses of retinal layers and choroid.

Full description

This proposed study is a 24-month longitudinal randomized trial that aims to investigate myopia development after either topical application of 0.05% atropine or prescription of DIMS lens in children with various predicted myopia progression rates by their initial retinal responses obtained by multifocal ERG. This will help elucidate the effectiveness of using 0.05% atropine and prescribing DIMS lens for myopia control in children with different myopia progression rates. The retinal electrophysiological investigation will help determine the contribution of L/M cones in juvenile myopia progression and changes of retinal activities under atropine and DIMS treatment.

80 subjects in either gender aged 7 to 9 years will be recruited in this study. They should have spherical equivalent refractive error between -0.5D and -4D in both eyes with best-corrected visual acuity of logMAR 0.00 or better. All should have normal eye health and without systemic diseases or epilepsy. They have not received any myopia control previously. Eligible subjects will have a baseline eye examination and have the first 6-month period monitoring the refractive and ocular changes compared with the baseline control data. After these 6 months, subjects will be classified into either fast or slow myopia progression group in accordance with the results of electrophysiology results and then will further be randomly allocated either intervention group: pharmacological treatment group (daily topical 0.05% atropine) or control group: non-pharmacological treatment group (daily wear of Defocused Incorporated Multiple Segments - DIMS lenses), for 18 months study period with 6-month interval regular follow up.

The primary outcomes are the changes of refractive errors and axial length after different types of interventions and the secondary outcomes are the relations between the parameters of mfERG responses and the thicknesses of retinal layers and choroid.

Enrollment

80 estimated patients

Sex

All

Ages

7 to 9 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • be aged between 7 and 9 years
  • have no reported eye disorder and no family history of eye disease
  • be able to participate in this study for 24 months
  • not have any current or history of epilepsy
  • not have any current or history of asthma
  • have refractive error between 0.50 D and 4.00 D and less than 1.50D of astigmatism with best corrected visual acuity of LogMAR 0.0 or better
  • have no detected eye diseases or disorders after eye examination, except myopia

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 2 patient groups

Atropine 0.05%
Active Comparator group
Description:
Group receiving atropine treatment for 18 months after 6 months of monitoring without intervention
Treatment:
Drug: Atropine 0.05%
DIMS lens
Experimental group
Description:
Group receiving DIMS lens treatment for 18 months after 6 months of monitoring without intervention
Treatment:
Device: DIMS lens

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Henry HL CHAN, PhD; Kaiyip CHOI, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems